Integra (IART) Q2 Revenue Beats by 5%
Integra LifeSciences (NASDAQ:IART), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most important takeaway was that the company’s revenue (GAAP) exceeded expectations, coming in at $415.6 million—well above the GAAP consensus estimate of $395.0 million. Adjusted EPS (non-GAAP) slightly surpassed forecasts as well, hitting $0.45 compared to the expected $0.44. Despite this sales outperformance, Integra recorded a $511 million non-cash goodwill impairment (GAAP) and faced falling margins along with negative free cash flow. The quarter highlighted persistent operational and profitability challenges, but also progress in core product demand and manufacturing stability.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Integra LifeSciences is a longtime provider of surgical tools and advanced medical products. Its primary customers include hospitals and surgeons who rely on Integra’s neurosurgery equipment, tissue reconstruction technology, and related devices to treat complex conditions.
Source Fool.com
Integra LifeSciences Holdings Corp Aktie
Bei der Aktie stehen derzeit 4 Sell-Einschätzungen 1 Buy-Einschätzungen gegenüber. Das Sentiment ist also eher negativ.
Ein negatives, aber moderates Potenzial für Integra LifeSciences Holdings Corp mit einem Kursziel von 10 € im Vergleich zu 10.5 €.
